| Year |
Citation |
Score |
| 2020 |
Boal LH, Glod J, Spencer M, Kasai M, Derdak J, Dombi E, Ahlman M, Beury DW, Merchant M, Persenaire C, Liewehr DJ, Steinberg SM, Widemann BC, Kaplan RN. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I related Plexiform Neurofibromas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32943455 DOI: 10.1158/1078-0432.Ccr-20-1696 |
0.353 |
|
| 2020 |
Chi SN, Bourdeaut F, Laetsch TW, Fouladi M, Macy ME, Makin GW, Shukla NN, Wetmore C, Margol AS, Casanova M, Kilburn LB, Yi J, Hargrave DR, McCowage GB, Pinto NR, ... ... Merchant M, et al. Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors. Journal of Clinical Oncology. 38: 10525-10525. DOI: 10.1200/Jco.2020.38.15_Suppl.10525 |
0.336 |
|
| 2016 |
Shukla NN, Somwar R, Smith RS, Ambati SR, Munoz S, Merchant MS, D'Arcy P, Wang X, Kobos R, Antczak C, Binder B, Shum D, Radu C, Yang G, Taylor BS, et al. Proteasome addiction defined in Ewing's sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors. Cancer Research. PMID 27256563 DOI: 10.1158/0008-5472.Can-16-1040 |
0.353 |
|
| 2015 |
D'Angelo S, Merchant M, Melchiori L, Zhang H, Pandite L, Holdich T, Binder-Scholl G, Tap W, Fortin M, Peretz Y, Wright M, Meyers P, Amado R, Jakobsen B, Mackall C. Optimizing engineered TCR T cell therapy for synovial sarcoma Journal For Immunotherapy of Cancer. 3: 159. DOI: 10.1186/2051-1426-3-S2-P159 |
0.306 |
|
| 2015 |
Melchiori L, Williams DD, Binder-Scholl GK, Wong R, Kreutz M, Tayton-Martin HK, Stadtmauer E, Vogl DT, Merchant M, Tap W, D'Angelo S, Davila E, Fortin M, Peretz Y, Rapoport AP, et al. 511. Enhanced-Affinity NY-ESO-1-Specific T Cells Exhibit Extended Functionality without Exhaustion in a Pattern of Effector and Memory Programming in Multiple Cancer Indications Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34120-X |
0.369 |
|
| 2014 |
Arnold MA, Ballester LY, Pack SD, Abdullaev Z, Merchant M, Tsokos MG. Primary subcutaneous spindle cell Ewing sarcoma with strong S100 expression and EWSR1-FLI1 fusion: a case report Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 17: 302-307. PMID 24735198 DOI: 10.2350/14-03-1454-Cr.1 |
0.325 |
|
| 2014 |
Shukla N, Somwar R, Ambati S, Smith RS, Merchant M, Kobos R, Ouerfelli O, Djaballah H, Ladanyi M. Abstract PR09: High-throughput chemical screening identifies a novel class of proteasome inhibitors with significant activity against Ewing sarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr09 |
0.363 |
|
| 2013 |
van Den Brink M, Leen AM, Baird K, Merchant M, Mackall C, Bollard CM. Enhancing immune reconstitution: from bench to bedside. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: S79-83. PMID 23041603 DOI: 10.1016/J.Bbmt.2012.09.016 |
0.31 |
|
| 2013 |
Sholler GL, Bergendahl G, VanderWerff A, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Neville K, Ashikaga T, Bond J, Hanna G, Merchant M, et al. Abstract LB-160: A feasibility trial using molecular-guided therapy for the treatment of patients with refractory or recurrent neuroblastoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-160 |
0.357 |
|
| 2012 |
Baird K, Fry TJ, Merchant M, Richards K, Delbrook C, Wayne AS, Mackall CL. Early Clinical Experience of aAPC Activated NK-DLI Following Allogeneic PBSCT in Pediatric Solid Tumor Patients. Blood. 120: 3013-3013. DOI: 10.1182/Blood.V120.21.3013.3013 |
0.323 |
|
| 2012 |
Shah NN, Merchant M, Cole D, Richards K, Delbrook C, Widemann BC, Wayne AS. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer Blood. 120: 1497-1497. DOI: 10.1182/Blood.V120.21.1497.1497 |
0.306 |
|
| 2010 |
Kayton ML, He M, Zakowski MF, Moreira AL, Lau C, Chou AJ, Merchant M, Merola PR, Wexler LH, La Quaglia MP, Travis WD, Ladanyi M. Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1764-71. PMID 20975376 DOI: 10.1097/Jto.0B013E3181F69F08 |
0.306 |
|
| 2010 |
Toretsky JA, Erkizan HV, Kong Y, Merchant M, Barber-Rotenberg JS, Brown ML, Üren A. Abstract 3411: Targeting of EWS-FLI1 with small molecule YK-4-279 reduces xenograft growth by disruption of disordered protein-protein interactions Cancer Research. 70: 3411-3411. DOI: 10.1158/1538-7445.Am10-3411 |
0.32 |
|
| 2009 |
Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nature Medicine. 15: 750-6. PMID 19584866 DOI: 10.1038/Nm.1983 |
0.349 |
|
| Show low-probability matches. |